PCSA

Processa Pharmaceuticals Inc

1.86

Oct 22 • 3:59 PM ET +0.10 (5.68%)

1.86

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: NCNA MBRX ACTU BYSI PPCB CRDF KZIA ATNM ELTX OSTX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	5.20M
Enterprise Value	5.00M
Income	-13.44M
Sales	0.00M
Book/sh	-0.11
Cash/sh	0.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Nov 21, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	26.00
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.87
Current Ratio	0.87
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-5.59
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	77.00% 61.77%
Sales past 3/5Y	- -
EPS Y/Y TTM	90.37%
Sales Y/Y TTM	-
EPS Q/Q	81.21%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	-13.64% -

Insider Own	14.79%
Insider Trans	14.89%
Inst Own	14.88%
Inst Trans	10.55%
ROA	-262.17%
ROE	-464.20%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	11.36%
SMA50	-2.09%
SMA200	-22.73%
Trades

Shs Outstand	2.79M
Shs Float	2.38M
Short Float	0.17%
Short Ratio	0.02
Short Interest	0.00M
52W High	10.84 -82.85%
52W Low	1.04 78.67%
Volatility	8.64% 12.96%
ATR (14)	0.19
RSI (14)	54.32
Beta	1.29
Rel Volume	0.06
Avg Volume	268.87K
Volume	16,151

Perf Week	10.71%
Perf Month	-1.59%
Perf Quarter	-28.46%
Perf Half Y	-37.79%
Perf YTD	-35.42%
Perf Year	-73.26%
Perf 3Y	-98.95%
Perf 5Y	-99.95%
Perf 10Y	-99.95%
Recom	2.00
Target Price	25.00
Prev Close	1.76
Price	1.86
Change %	5.68%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-24	Initiated	H.C. Wainwright	Buy	$8

Sep-01-26 07:00AM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-29-26 10:33AM	Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline (InvestorsHub) -33.44%
07:30AM	PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS (GlobeNewswire)
Jan-12-26 09:15AM	Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.55%
Jan-05-26 09:15AM	Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study (GlobeNewswire) +10.24%
09:21AM	Loading…
Dec-18-25 09:21AM	PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study (Zacks) -41.62%
Dec-17-25 08:00AM	Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer (GlobeNewswire) +122.30%
Nov-05-25 09:15AM	Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 (GlobeNewswire)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:30AM	Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies (GlobeNewswire)
Jul-11-25 07:26PM	Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress (Insider Monkey) -5.26%
Jul-01-25 09:00AM	Processa Pharmaceuticals Provides Portfolio and Business Update (GlobeNewswire)
Jun-17-25 12:26PM	Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering (GlobeNewswire) +15.50%
09:00AM	Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate (GlobeNewswire)
Jun-13-25 08:00AM	Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025 (GlobeNewswire) -24.92%
09:00AM	Loading…
May-30-25 09:00AM	Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting (GlobeNewswire)
Apr-15-25 08:00AM	Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025 (GlobeNewswire)
Mar-18-25 08:30AM	Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference (GlobeNewswire) -5.11%
Feb-21-25 03:48AM	Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently (Insider Monkey)
Feb-07-25 08:00AM	Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference (GlobeNewswire) +10.42%
Jan-30-25 05:17PM	Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +10.57%
Jan-27-25 08:30PM	Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -10.32%
Oct-30-24 04:15PM	Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results (GlobeNewswire) -13.16%
Oct-02-24 04:05PM	Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer (GlobeNewswire)
Sep-03-24 08:00AM	Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September (GlobeNewswire)
Aug-28-24 08:00AM	Processa Pharmaceuticals Provides Product Pipeline and Financial Update (GlobeNewswire)
Aug-19-24 08:00AM	Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri (GlobeNewswire)
Jul-30-24 08:00AM	Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer (GlobeNewswire) +34.12%
Jul-17-24 08:00AM	Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer (GlobeNewswire)
Jun-11-24 08:20AM	Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer (GlobeNewswire) +13.92%
10:53AM	Loading…
May-13-24 10:53AM	PCSA Stock Earnings: Processa Pharma Reported Results for Q1 2024 (InvestorPlace) +6.22%
May-06-24 08:00AM	Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference (GlobeNewswire) +8.29%
Apr-30-24 08:00AM	Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research (GlobeNewswire)
Apr-11-24 08:00AM	Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial (GlobeNewswire)
Mar-28-24 08:15AM	Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference (GlobeNewswire)
Mar-25-24 08:15AM	Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Feb-21-24 08:15AM	Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -8.47%
Feb-14-24 01:00PM	Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference (GlobeNewswire)
Feb-06-24 08:30AM	Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Feb-01-24 04:22PM	Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering (GlobeNewswire)
Jan-26-24 09:04AM	Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -28.04%
Jan-25-24 02:40PM	Why Is Processa Therapeutics (PCSA) Stock Up 90% Today? (InvestorPlace) +148.78%
08:30AM	Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses (GlobeNewswire)
Jan-19-24 07:45AM	Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer (GlobeNewswire) +10.84%
Jan-18-24 07:45AM	Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split (GlobeNewswire) -25.31%
Jan-02-24 05:06PM	Processa Pharmaceuticals to Present at the Biotech Showcase 2024 (GlobeNewswire) +5.71%
Dec-19-23 09:00AM	Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine (GlobeNewswire) -21.36%
Dec-13-23 09:00AM	Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine (GlobeNewswire) -25.40%
Nov-30-23 08:15AM	Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference (GlobeNewswire) +20.53%
Nov-29-23 08:15AM	Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook (GlobeNewswire) +17.95%
Nov-13-23 01:40PM	Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson (GlobeNewswire) +20.68%
Nov-09-23 08:15AM	Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas (GlobeNewswire) -6.72%
Nov-01-23 08:15AM	Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders (GlobeNewswire)
Oct-13-23 01:08PM	Processa Pharmaceuticals to Present at the ThinkEquity Conference (GlobeNewswire) +45.41%
Sep-06-23 08:15AM	Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-17-23 08:05AM	Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care (GlobeNewswire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-10-23 04:15PM	Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference (GlobeNewswire) +7.82%
Aug-08-23 08:15AM	Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer (GlobeNewswire)
Jun-14-23 04:15PM	Next Generation Chemotherapy: Improved Treatment for More Patients (GlobeNewswire) -11.52%
Jun-13-23 08:30AM	Longeveron Welcomes Three New Prominent Board Members (GlobeNewswire) -5.45%
May-22-23 08:05AM	Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress (GlobeNewswire)
May-18-23 08:00AM	Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative (GlobeNewswire)
Apr-28-23 08:15AM	Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting (GlobeNewswire) +14.46%
Mar-30-23 04:01PM	Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results (GlobeNewswire) +5.63%
Mar-23-23 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST (GlobeNewswire)
Mar-17-23 08:30AM	Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine (GlobeNewswire) +10.64%
Mar-07-23 08:30AM	Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 08:30AM	Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies (GlobeNewswire)
Feb-15-23 08:30AM	Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules (GlobeNewswire)
Feb-10-23 08:00AM	Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules (GlobeNewswire)
Jan-04-23 08:30AM	Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023. (GlobeNewswire)
Dec-14-22 08:30AM	Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial (GlobeNewswire)
Nov-08-22 04:00PM	Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
08:30AM	PCS12852 Improves Gastric Emptying in Gastroparesis Patients (GlobeNewswire)
Nov-02-22 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST (GlobeNewswire) -6.38%
Nov-01-22 08:30AM	Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial (GlobeNewswire) +7.75%
Sep-15-22 08:30AM	Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs (GlobeNewswire)
Sep-07-22 08:30AM	Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022 (GlobeNewswire)
Aug-16-22 08:30AM	Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board (GlobeNewswire)
Aug-12-22 09:30AM	Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-22 03:00PM	Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST (GlobeNewswire)
Aug-04-22 09:30AM	Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 (GlobeNewswire)
Aug-03-22 04:00PM	Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 (GlobeNewswire)
Jul-12-22 08:30AM	Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022 (GlobeNewswire)
Jun-24-22 09:06AM	Here's Why We're Watching Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Situation (Simply Wall St.) +5.21%
May-12-22 04:20PM	Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.94% -7.18%
May-05-22 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST (GlobeNewswire)
Apr-20-22 08:30AM	Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine) (GlobeNewswire)
Apr-05-22 08:30AM	Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis (GlobeNewswire)
Mar-30-22 04:00PM	Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update (GlobeNewswire)
Mar-23-22 08:30AM	Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST (GlobeNewswire)
Mar-10-22 08:30AM	Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-26-22 08:15AM	Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022 (GlobeNewswire)
Jan-17-22 08:42AM	Multiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Nov-11-21 04:05PM	Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update (GlobeNewswire)
Nov-04-21 08:15AM	Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis (GlobeNewswire)
Oct-26-21 08:30AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST (GlobeNewswire)
Oct-19-21 10:22AM	What Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares? (Simply Wall St.) -6.74%
Oct-12-21 08:30AM	Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guy Wendy	Chief Administrative Officer	Jun 30 '26	Buy	1.93	2,436	4,701	14,394	Jul 01 04:20 PM
Lin Patrick	Chief Business - Strategy Off	Jun 30 '26	Buy	1.93	2,106	4,065	13,113	Jul 01 04:19 PM
Ng George K	Chief Executive Officer	Jul 01 '26	Buy	1.93	3,057	5,900	15,492	Jul 01 04:19 PM
SKIBSTED RUSSELL	Chief Financial Officer	Jun 30 '26	Buy	1.93	3,277	6,325	16,689	Jul 01 04:17 PM
Young David	Pres. Research & Development	Jun 30 '26	Buy	1.93	2,531	4,885	21,729	Jul 01 04:16 PM
Young David	Pres. Research & Development	Jun 15 '26	Buy	2.22	2,067	4,589	19,198	Jun 16 04:24 PM
SKIBSTED RUSSELL	Chief Financial Officer	Jun 15 '26	Buy	2.22	2,654	5,892	13,412	Jun 16 04:23 PM
Ng George K	Chief Executive Officer	Jun 15 '26	Buy	2.22	2,465	5,472	12,435	Jun 16 04:22 PM
Lin Patrick	Chief Business - Strategy Off	Jun 15 '26	Buy	2.22	1,831	4,065	11,007	Jun 16 04:21 PM
Guy Wendy	Chief Administrative Officer	Jun 15 '26	Buy	2.22	2,118	4,702	11,958	Jun 16 04:20 PM
Young David	Pres. Research & Development	May 29 '26	Buy	2.57	1,786	4,590	17,131	Jun 01 05:01 PM
SKIBSTED RUSSELL	Chief Financial Officer	May 29 '26	Buy	2.57	2,292	5,890	10,758	Jun 01 04:59 PM
Ng George K	Chief Executive Officer	May 29 '26	Buy	2.57	2,129	5,472	9,970	Jun 01 04:58 PM
Lin Patrick	Chief Business - Strategy Off	May 29 '26	Buy	2.57	1,582	4,066	9,176	Jun 01 04:56 PM
Guy Wendy	Chief Administrative Officer	May 29 '26	Buy	2.57	1,829	4,701	9,840	Jun 01 04:55 PM
Ng George K	Chief Executive Officer	May 15 '26	Buy	2.97	1,843	5,474	7,841	May 19 06:06 PM
Young David	Pres. Research & Development	May 15 '26	Buy	2.97	1,545	4,589	15,345	May 19 06:04 PM
Lin Patrick	Chief Business - Strategy Off	May 15 '26	Buy	2.97	1,369	4,066	7,594	May 19 06:02 PM
Guy Wendy	Chief Administrative Officer	May 15 '26	Buy	2.97	1,583	4,702	8,011	May 19 05:37 PM
SKIBSTED RUSSELL	Chief Financial Officer	May 15 '26	Buy	2.97	1,984	5,892	8,466	May 19 05:35 PM
Young David	Pres. Research & Development	Apr 30 '26	Buy	2.69	1,706	4,589	13,813	May 01 04:39 PM
SKIBSTED RUSSELL	Chief Financial Officer	Apr 30 '26	Buy	2.69	2,190	5,891	6,498	May 01 04:38 PM
Ng George K	Chief Executive Officer	Apr 30 '26	Buy	2.69	2,034	5,471	6,013	May 01 04:37 PM
Lin Patrick	Chief Business - Strategy Off	Apr 30 '26	Buy	2.69	1,511	4,065	6,236	May 01 04:36 PM
Guy Wendy	Chief Administrative Officer	Apr 30 '26	Buy	2.69	1,748	4,702	6,441	May 01 04:35 PM
Bigora Sian	Chief Development Officer	Apr 30 '26	Buy	2.69	1,986	5,342	7,496	May 01 04:34 PM
Young David	Pres. Research & Development	Apr 15 '26	Buy	2.97	1,545	4,589	12,107	Apr 17 04:55 PM
Ng George K	Chief Executive Officer	Apr 15 '26	Buy	2.97	1,843	5,474	5,492	Apr 17 04:54 PM
Lin Patrick	Chief Business - Strategy Off	Apr 15 '26	Buy	2.97	1,369	4,066	4,725	Apr 17 04:52 PM
Guy Wendy	Chief Administrative Officer	Apr 15 '26	Buy	2.97	1,583	4,702	4,693	Apr 17 04:51 PM
Bigora Sian	Chief Development Officer	Apr 15 '26	Buy	2.97	1,799	5,343	5,510	Apr 17 04:50 PM
SKIBSTED RUSSELL	Chief Financial Officer	Apr 15 '26	Buy	2.97	1,984	5,892	4,308	Apr 17 04:49 PM
Neal James R	Director	Mar 31 '26	Buy	2.54	789	2,000	818	Apr 02 05:12 PM
Young David	Pres. Research & Development	Mar 31 '26	Buy	2.54	1,810	4,588	10,562	Apr 01 05:20 PM
SKIBSTED RUSSELL	Chief Financial Officer	Mar 31 '26	Buy	2.54	2,324	5,891	2,324	Apr 01 05:18 PM
Pannu Geraldine	Director	Mar 31 '26	Buy	2.54	2,072	5,253	2,188	Apr 01 05:17 PM
Ng George K	Chief Executive Officer	Mar 31 '26	Buy	2.54	2,136	5,415	3,649	Apr 01 05:15 PM
Lin Patrick	Chief Business - Strategy Off	Mar 31 '26	Buy	2.54	1,603	4,064	3,356	Apr 01 05:11 PM
Guy Wendy	Chief Administrative Officer	Mar 31 '26	Buy	2.54	1,854	4,700	3,110	Apr 01 05:09 PM
Bigora Sian	Chief Development Officer	Mar 31 '26	Buy	2.54	2,107	5,341	3,711	Apr 01 05:08 PM
Baluch Khoso	Director	Mar 31 '26	Buy	2.54	2,269	5,752	2,325	Apr 01 05:06 PM
Young David	Pres. Research & Development	Jan 01 '26	Option Exercise	0.00	49	0	8,752	Feb 04 05:09 PM
Lin Patrick	Chief Business - Strategy Off	Jan 01 '26	Option Exercise	0.00	193	0	1,753	Feb 04 05:07 PM
Guy Wendy	Chief Administrative Officer	Jan 01 '26	Option Exercise	0.00	193	0	1,256	Feb 04 05:05 PM
Bigora Sian	Chief Development Officer	Jan 01 '26	Option Exercise	0.00	249	0	1,604	Feb 04 05:04 PM

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

J.D.Mr. George K. Ng Esq.

Chief Financial OfficerMr. Russell L. Skibsted M.B.A.

Pharm.D.Dr. David Young Ph.D.

Co-FounderMr. Patrick Lin

Co-FounderMs. Wendy J. Guy

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCSA

Processa Pharmaceuticals Inc

Upgrade your Finviz experience